CBL antibody

Cannot supply to this region.

SKU:: GTX50669
Additional Names:: Cbl proto-oncogene , C-CBL , CBL2 , FRA11B , NSLL , RNF55
Application:: WB, IHC-P
Concentration:: 1 mg/ml
Physical State:: Liquid
Species Reactivity:: Human
Purification:: Affinity Purified
Storage Conditions:: -20[o]C Aliquot. Avoid freeze/thaw cycles. Store undiluted., 2-8[o]C Aliquot. Avoid freeze/thaw cycles. Store undiluted., -20[o]C/-70[o]C Aliquot. Avoid freeze/thaw cycles. Store undiluted.
Supplier:: Genetex
Host:: Rabbit
Reactivities:: Human
Buffer:: PBS, 150mM NaCl, 50% Glycerol, 0.02% Sodium azide.
Immunogen:: Peptide sequence around aa. 698~702 (T-E-Y-M-T) derived from human CBL.
Uniprot:: P22681
Synonyms:: C-CBL;Cas-Br-M (murine) ecotropic retroviral transforming sequence;casitas B-lineage lymphoma proto-oncogene;Cbl proto-oncogene, E3 ubiquitin protein ligase;CBL2;E3 ubiquitin-protein ligase CBL;FRA11B;fragile site, folic acid type, rare, fra(11)(q23.3);NSLL;oncogene CBL2;proto-oncogene c-Cbl;RING finger protein 55;RING-type E3 ubiquitin transferase CBL;RNF55;signal transduction protein CBL
Extra Details:: This gene is a proto-oncogene that encodes a RING finger E3 ubiquitin ligase. The encoded protein is one of the enzymes required for targeting substrates for degradation by the proteasome. This protein mediates the transfer of ubiquitin from ubiquitin conjugating enzymes (E2) to specific substrates. This protein also contains an N-terminal phosphotyrosine binding domain that allows it to interact with numerous tyrosine-phosphorylated substrates and target them for proteasome degradation. As such it functions as a negative regulator of many signal transduction pathways. This gene has been found to be mutated or translocated in many cancers including acute myeloid leukaemia, and expansion of CGG repeats in the 5' UTR has been associated with Jacobsen syndrome. Mutations in this gene are also the cause of Noonan syndrome-like disorder. [provided by RefSeq, Jul 2016]

Shipping Conditions:: Blue Ice